Perceptive Imaging Appoints Doug Fulling as CEO to Lead Global Growth, Enhance Services, and Drive Innovation in Clinical Trial Imaging
Perceptive Imaging (“Perceptive” or “the Company”), a global leader in clinical trial imaging services for the pharmaceutical and biotech industries, has announced a key leadership transition with the appointment of Doug Fulling as its new Chief Executive Officer, effective October 1, 2025. Fulling succeeds David Herron, who has served as CEO since 2022 and will continue to contribute to the company’s strategic direction as a member of its Board of Directors.
The appointment marks an important new chapter for Perceptive Imaging as it continues to expand its influence in the global clinical research landscape. Under Fulling’s leadership, the company aims to accelerate growth, deepen client partnerships, and pioneer new imaging technologies that enhance the efficiency and accuracy of clinical development. The transition also reflects Perceptive’s ongoing commitment to operational excellence, innovation, and service quality—core values that have underpinned its rise as a trusted partner for top pharmaceutical and biotechnology companies worldwide.
A Proven Leader with Deep Industry Experience
Doug Fulling brings over 25 years of executive leadership and commercial strategy experience in the life sciences sector, spanning business development, operational management, and organizational transformation. Prior to joining Perceptive Imaging, Fulling served as President of Precision AQ, a division of Precision Medicine Group, where he was instrumental in developing integrated solutions that bridged clinical insights with real-world data to support evidence generation and market access strategies.
Before that, he held the role of President of Symphony Health, part of ICON Plc, one of the world’s leading clinical research organizations. In these roles, Fulling oversaw large-scale business operations, led cross-functional global teams, and consistently delivered sustainable growth through innovation, collaboration, and data-driven decision-making.
Earlier in his career, Fulling held senior leadership positions with PRA Health Sciences and MDS Pharma Services, where he played key roles in expanding global operations and enhancing service delivery models. His extensive track record demonstrates his ability to lead high-performing teams, build strategic partnerships, and implement scalable business frameworks—capabilities that will be crucial as Perceptive Imaging continues to grow its global footprint.
Strengthening Perceptive’s Position in the Clinical Imaging Landscape
Perceptive Imaging has experienced strong momentum in recent years, driven by its customer-centric business model, technological advancements, and commitment to quality. The company specializes in providing comprehensive imaging solutions that support all phases of clinical development—from early discovery to late-stage regulatory submissions—enabling researchers to collect, analyze, and interpret imaging data with precision and efficiency.
As of June 30, 2025, Perceptive Imaging had supported nearly 400 regulatory approvals worldwide, underscoring its pivotal role in the successful commercialization of innovative therapies across multiple therapeutic areas, including oncology, neurology, cardiology, and rare diseases. The company’s clients include Top 20 global pharmaceutical companies, mid-sized biotech firms, and emerging innovators seeking world-class imaging support for their clinical programs.
Perceptive’s success stems from its ability to combine scientific rigor with operational agility. By continuously investing in AI-enabled image analysis, cloud-based workflow solutions, and centralized data management platforms, the company has positioned itself at the forefront of imaging science innovation. These capabilities not only enhance the precision of trial data but also reduce variability, speed up decision-making, and improve the overall quality of clinical outcomes.
A Strategic Vision for the Future
As CEO, Doug Fulling will lead Perceptive Imaging through its next phase of expansion, focusing on three key strategic priorities:
- Accelerating Growth:
Fulling’s appointment aligns with Perceptive’s broader ambition to scale its operations globally, deepen client relationships, and diversify its service portfolio. The company plans to expand its geographical presence and enhance its capacity to meet increasing demand from pharmaceutical sponsors conducting large, multi-center clinical trials. - Enhancing Client Services:
Under Fulling’s leadership, Perceptive will further refine its service delivery model to improve client experience and operational efficiency. This includes streamlining study startup timelines, enhancing data transparency, and offering more flexible engagement models that align with the evolving needs of biopharma clients. - Driving Technological Innovation:
Innovation remains at the core of Perceptive’s mission. The company will continue to invest in developing next-generation imaging technologies, such as advanced quantitative imaging biomarkers, machine learning algorithms for image interpretation, and real-time image quality monitoring tools. These innovations are expected to significantly improve the accuracy and reproducibility of imaging endpoints in clinical trials.
Commenting on his new role, Doug Fulling expressed enthusiasm about joining Perceptive Imaging at a pivotal time in its evolution:
“Perceptive Imaging has undergone significant transformation in recent years and is strongly positioned to embark on the next chapter of the company’s development. I have followed Perceptive’s evolution for more than a decade and am very honored to join the team at such an exciting time. I look forward to working with my new colleagues and our clients to deliver the imaging solutions and services needed to bring new medical treatments to patients sooner.As David Herron transitions to a Board role, we thank him for all the work he has done during his tenure as CEO to evolve Perceptive Imaging into a highly sophisticated healthcare platform with very exciting future prospects.”
A Legacy of Transformation Under David Herron
Since assuming leadership in 2022, David Herron has played an instrumental role in transforming Perceptive Imaging into a global imaging powerhouse. Under his direction, the company implemented a series of strategic initiatives that modernized its technology infrastructure, strengthened its operational processes, and enhanced its client engagement model.
Herron led Perceptive through a period of sustained growth, securing long-term partnerships with several top-tier pharmaceutical companies and expanding the company’s service offerings across key therapeutic areas. He was also a key advocate for adopting AI-driven analytics and digital imaging platforms, initiatives that significantly improved efficiency and data quality across studies.
Reflecting on the leadership transition, Herron shared his confidence in the company’s continued success under Fulling’s guidance:
We are very pleased to appoint an executive of Doug Fulling’s caliber to lead Perceptive Imaging into the future. His wealth of experience and proven track record of scaling organizations with integrity and vision, along with all our people’s incredible expertise, knowledge, and dedication, will leave Perceptive well positioned to realize our ambitious plans.
I am incredibly proud of what the team and I have built together in recent years and excited for what lies ahead. I know Perceptive will continue to thrive under Doug’s leadership and look forward to supporting him and the team as a member of the Board to drive innovation and cultivate new strategic partnerships that position Perceptive and its clients for long-term success.”
Empowering Clinical Research Through Imaging Science
At the heart of Perceptive Imaging’s mission is a commitment to empowering clinical researchers with the imaging tools, expertise, and insights necessary to accelerate therapeutic innovation. The company’s integrated imaging solutions play a critical role in helping sponsors evaluate the safety and efficacy of new therapies, enabling more confident regulatory submissions and faster approvals.
Perceptive’s services cover a wide range of imaging modalities, including MRI, CT, PET, ultrasound, and X-ray, as well as advanced imaging biomarkers and quantitative techniques. Its multidisciplinary team of imaging scientists, radiologists, and data specialists works collaboratively with clients to ensure high-quality image acquisition, standardized data interpretation, and regulatory compliance.
Through continuous process improvement and close collaboration with clinical investigators, Perceptive Imaging has built a reputation for excellence in supporting both early-phase and late-stage clinical programs. This reputation has made it a trusted partner to pharmaceutical and biotech companies striving to bring life-changing therapies to market.
Building a Smarter, More Connected Future
As Perceptive Imaging enters its next era under Doug Fulling’s leadership, the company’s focus on growth, innovation, and collaboration will remain central. With a strong foundation of scientific excellence, a dedicated global team, and a robust client network, Perceptive is well-positioned to lead the next wave of transformation in clinical trial imaging.
The leadership transition represents more than just a change in executive roles—it symbolizes Perceptive Imaging’s readiness to evolve into a more agile, technology-driven, and client-focused organization. As clinical research becomes increasingly complex and data-driven, Perceptive’s ability to combine imaging science with digital innovation will be key to enabling faster, smarter, and more successful drug development.
With Doug Fulling at the helm and David Herron continuing to guide strategy from the Board, Perceptive Imaging is poised for a new phase of dynamic growth, reinforcing its role as a cornerstone partner in the global clinical research ecosystem—helping bring tomorrow’s medical breakthroughs to patients worldwide.
